Reports
The following list of reports reflects the latest in findings and outcomes in medical research as presented at major medical meetings and published peer-reviewed medical journals. In this section you can view reports from important congresses as well as summaries of some recently published journal articles. Please let us know if you have a particular area of interest you would like to see covered.
PRIORITY PRESS - 18th Annual International Congress of the International Liver Transplantation Society
Simultaneous Antiviral and Immunosuppressive Treatment Strategies in Liver Transplantation
San Francisco, California / May 16-19, 2012
San Francisco - Long-term outcome of patients undergoing liver transplantation as a result of the complications of hepatitis C viral (HCV) infection is predicted to improve with studies demonstrating that immunosuppressive drugs can be used...
RESOURCE LINE
VACCINE
Spring 2012
NACI: New recommendations for the quadrivalent HPV vaccine for malesNational Advisory Committee on Immunization. Canada Communicable Disease Report January 2012;38:ACS-7. Recommendations for the use of the quadrivalent human papillomavirus...
PRIORITY PRESS - CACMID-AMMI Canada 2012 Annual Conference
Invasive Fungal Infections in Severely Immunocompromised Patients: Strategies to Improve Overall Survival
Vancouver, British Columbia / May 3-5, 2012
Vancouver - Invasive fungal infections (IFIs) affect mainly patients with hematological malignancies undergoing hematopoietic stem cell transplantation. Invasive aspergillosis (IA) accounts for the majority of these infections and it can be...
PRIORITY PRESS - 22nd European Congress on Clinical Microbiology and Infectious Diseases (ECCMID)
Primary Treatment of Invasive Aspergillosis in Hematology Patients
London, UK / March 31- April 3, 2012
London - The first randomized study of combination therapy in the treatment of invasive aspergillosis (IA) has provided new evidence-based guidance for hematological malignancy patients, including allograft hematopoietic stem cell...
PHYSICIAN PERSPECTIVE - Viewpoint based on the following articles: Santolaya et al. Lancet 2012;379:617-24, Gossger et al. JAMA 2012;307(6):573-82.
Closing the Gap on N. meningitidis: Potential for Imminent Disease Control
April 2012
Guest Editor: Ronald Gold, MD, MPHFormer Head, Division of Infectious DiseaseThe Hospital for Sick ChildrenToronto, OntarioProfessor of Pediatrics (Retired) Faculty of Medicine, University of TorontoMedical AdvisorMeningitis Research...
PRIORITY PRESS - 22nd European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)
Real-world Clinical Experience Treating Gram-positive Infections
London, UK / March 31-April 3, 2012
London - Several new sets of data were presented at ECCMID that provided guidance on the efficacy of some of the most effective antibiotics for the treatment of serious Gram-positive infections. One of these was the ongoing European...
PRIORITY PRESS - McGill Faculty of Medicine 62nd Annual Refresher Course for Family Physicians
Update on Paediatrics: Immunization, Progress and Recommendations
Montréal, Quebec / December 5-7, 2011
Montréal - During this year’s widely attended McGill Refresher Course, delegates learned of recent National Advisory Committee on Immunization (NACI) updates for immunization against 3 paediatric diseases. NACI recommends that...
PRIORITY PRESS - Family Medicine Forum 2011
Achieving Broad Protection Against Serogroup B: Vaccine Targets Most Common Meningococcus Serogroup
Montréal, Quebec / November 3-5, 2011
Montréal - Recent surveys suggest poor control of symptoms and disease is endemic among patients with asthma and chronic obstructive pulmonary disease. There are numerous reasons for this finding, including lack of awareness of the...
PRIORITY PRESS - 49th Annual Meeting of the Infectious Diseases Society of America (IDSA)
Progress in Pneumococcal Vaccine Development
Boston, Massachusetts / October 20-23, 2011
Boston - Current immunization guidelines support administration of the 23-valent pneumococcal polysaccharide vaccine (PPSV23) to adults older than 65 and to selected at-risk populations in the age range of 18-65. Revaccination with PPSV23...